Novavax CEO Says Its Coronavirus Vaccine Could Win FDA Approval in May

The U.S. might be only a few weeks away from getting a fourth authorized coronavirus vaccine. That, at least, is the opinion of Novavax CEO Stanley Erck. On Monday, Erck said that his company's NVX-CoV2373 vaccine candidate could be granted emergency use authorization (EUA) approval by the Food and Drug Administration (FDA). That's conditional on the results of a phase 3 clinical trial involving 15,000 people in the U.K., the analysis of which should be completed in a matter of weeks.